Navidea wins NIH grant for beta-amyloid agent
Article Thumbnail ImageSeptember 4, 2013 -- Radiopharmaceutical developer Navidea Biopharmaceuticals has been awarded a grant from the National Institute on Aging of the U.S. National Institutes of Health (NIH).

To get access to this article and all of the content on, create a free account or sign-in now.
Member Sign In:
  MemberID or E-mail Address:

New Members

Becoming a Member is FREE!

  • Real-time radiology-specific news
  • Case of the Day and Teaching Files
  • Focused topics digital communities
  • Lively, discussion groups
  • Medical imaging bookstore
  • SalaryScan
  • Job Boards
  • Online CME
  • Bookstore, market reports, more …
  • Conference Calendar
  • User-controlled eNewsletters
  • … registration is FREE and easy!
  • The award is a Small Business Innovation Research (SBIR) grant for developing the company's NAV4694 beta-amyloid imaging agent. The grant will partially support a phase IIB clinical study evaluating NAV4694 as a diagnostic imaging agent that may aid physicians in identifying those individuals with mild cognitive impairment who are at greatest risk of progressing to Alzheimer's disease.

    If fully funded, the grant has the potential to provide up to $2.3 million in support through the conclusion of the clinical study, according to Navidea.

    || About || Advertising || || Bookstore || Breast MRI || Career Center || Case of the Day || Communities || Conferences || Contact Us || ECR News 2013 || Education || Equipment Classifieds || Europe || Facebook || Forums || Home || Links || Marketplace || Middle East || Mobile || Molecular Breast Imaging || New Installations || News in Brief || People in the News || Privacy Policy || RSNA News 2013 || Reference || Salary Survey Results || Trends in Radiology || Twitter || Vendor Connect || Webinars || XML/RSS ||

    Copyright © 2014 All Rights Reserved.